# Full Project 1: Understanding and Targeting of Convergent Immunosuppressive Pathways and Molecular Signaling in HPV-positive and HPV-negative Penile Cancer

> **NIH NIH U54** · UNIVERSITY OF TX MD ANDERSON CAN CTR · 2020 · $77,754

## Abstract

FULL PROJECT 1 - UNDERSTANDING AND TARGETING OF CONVERGENT IMMUNOSUPPRESSIVE 
PATHWAYS AND MOLECULAR SIGNALING IN HPV-POSITIVE AND HPV-NEGATIVE PENILE CANCER 
PROJECT SUMMARY/ABSTRACT 
Penile cancer (PeCa) is a highly morbid disease that exhibits a higher mortality among Puerto Ricans than 
among the rest of the US population. The theme of the U54 grant, Infection-Driven Malignancies Program for 
Advancing Careers and Translational Sciences (IMPACT), fits well with our project because infection with 
human papillomavirus (HPV) has been identified as a risk factor for penile cancer. The etiology of penile 
cancer is incompletely understood. Therefore, there is an urgent need to address knowledge gaps. We 
recently developed the first genetically engineered mouse (GEM) models of penile squamous cell carcinoma 
(PSCC), the predominant histologic type of PeCa, through co-deletion of tumor suppressor genes (Smad4, 
Apc) in mouse penile epithelium. We have also generated the first set of patient-derived xenograft (PDX) 
models for PeCa (N=6). In our pilot project, using this GEM model of PSCC, we found: (1) substantial 
infiltration of immune cells in the penile tumors, especially myeloid-derived suppressor cells (MDSCs) that can 
inhibit cytotoxic T cells and cause immune evasion, and (2) strong cyclooxygenase-2 (COX2) expression in 
penile tumors and PI3K/mTOR signaling in MDSCs. Further using expression arrays we identified novel 
insights into expression patterns associated with human HPV+ and HPV- PeCa.The objective of this proposal is 
to develop therapeutic strategies for PeCa and validate molecular pathways associated with HPV+ and HPV- 
PeCa subtypes. Our hypotheses are that (1) PeCa formation is promoted by chronic inflammation as a result of 
HPV infection or downregulation of essential tumor suppressor genes SMAD4 and APC, (2) The key signaling 
hubs driving PeCa progression, including COX2 and PD-L1 upregulation, are effective targets for 
immunotherapeutic intervention,and (3) Estrogen and Notch signaling are upregulated in HPV+ PeCa and play 
important roles in PeCa progression. The specific aims of this proposal are to: (Aim 1) Eradicate mouse penile 
cancer by combining targeted therapy and immunotherapy, (Aim 2) Identify the immunologic profiles 
associated with HPV infection in human penile cancer to optimize therapy, and (Aim 3) Validate and target 
both Estrogen and Notch signaling in HPV+ penile cancer. The proposed studies will have a significant impact 
on both the understanding of the molecular pathways that drive HPV+ and HPV- PeCa subtypes and the 
identification of effective therapeutic strategies to treat these highly morbid tumors. Through this unique 
collaboration our multidisciplinary research teams from The University of Texas MD Anderson Cancer Center 
and the University of Puerto Rico are poised make novel contributions to understanding and curing this rare 
fatal cancer.

## Key facts

- **NIH application ID:** 10249309
- **Project number:** 3U54CA096300-17S1
- **Recipient organization:** UNIVERSITY OF TX MD ANDERSON CAN CTR
- **Principal Investigator:** Curtis Pettaway
- **Activity code:** U54 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $77,754
- **Award type:** 3
- **Project period:** 2002-08-16 → 2024-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10249309

## Citation

> US National Institutes of Health, RePORTER application 10249309, Full Project 1: Understanding and Targeting of Convergent Immunosuppressive Pathways and Molecular Signaling in HPV-positive and HPV-negative Penile Cancer (3U54CA096300-17S1). Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/grant/nih/10249309. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*
